Literature DB >> 18923969

Normative data and psychometric properties for qualitative and quantitative scoring criteria of the Five-point Test.

Simone Goebel1, Regina Fischer, Roman Ferstl, Hubertus Maximilian Mehdorn.   

Abstract

The Five-point Test (Regard, Strauss, & Knapp, 1982) was introduced for the measurement of figural fluency as part of the examination of executive functions. Until now, no differentiated norms exist. We present normative data for adults aged 18-80 (n = 280) for the number of unique designs (productivity), the percent of perseverations (flexibility), the percent of rotated (strategic) designs, and the number of rule breakings. As age and education were correlated with test performance, norms were stratified by these two variables. Test-retest reliability and inter-rater reliability were calculated. Moreover, convergent and divergent validity as well as factorial validity were assessed through intercorrelations and correlations with other neuropsychological tests. All together, the Five-point Test proved to be reliable and valid.

Mesh:

Year:  2008        PMID: 18923969     DOI: 10.1080/13854040802389185

Source DB:  PubMed          Journal:  Clin Neuropsychol        ISSN: 1385-4046            Impact factor:   3.535


  18 in total

1.  Design fluency and neuroanatomical correlates in 54 neurosurgical patients with lesions to the right hemisphere.

Authors:  Dario Marin; Eleonora Madotto; Franco Fabbro; Miran Skrap; Barbara Tomasino
Journal:  J Neurooncol       Date:  2017-07-04       Impact factor: 4.130

2.  Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years.

Authors:  Sarah D Broicher; Linard Filli; Olivia Geisseler; Nicole Germann; Björn Zörner; P Brugger; M Linnebank
Journal:  J Neurol       Date:  2018-02-20       Impact factor: 4.849

3.  A missing piece? Neuropsychiatric functioning in untreated patients with tumors within the cerebellopontine angle.

Authors:  Simone Goebel; Hubertus Maximilian Mehdorn
Journal:  J Neurooncol       Date:  2018-07-07       Impact factor: 4.130

4.  The Modified Five-Point Test: normative data for a sample of Italian healthy adults aged 16-60.

Authors:  Raffaella Cattelani; Flora Dal Sasso; Delfina Corsini; Lucio Posteraro
Journal:  Neurol Sci       Date:  2011-02-16       Impact factor: 3.307

5.  Untimed Design Fluency in Aging and Alzheimer's Disease: Psychometrics and Normative Data.

Authors:  Preeti Sunderaraman; Elisaveta Sokolov; Sarah Cines; Elizabeth Sullo; Aidan Orly; Bianca Lerer; Jason Karlawish; Edward Huey; Stephanie Cosentino
Journal:  Appl Neuropsychol Adult       Date:  2015-02-13       Impact factor: 2.248

6.  Psychoneuroendocrine protocol to comprehensively study sexually dimorphic cognition.

Authors:  Sarah Kheloui; Mathias Rossi; Silke Jacmin-Park; Ophélie Larocque; Morgan Vallée; Philippe Kerr; Olivier Bourdon; Robert-Paul Juster
Journal:  Compr Psychoneuroendocrinol       Date:  2021-03-19

7.  Reference data for the Ruff Figural Fluency Test stratified by age and educational level.

Authors:  Gerbrand J Izaks; Hanneke Joosten; Janneke Koerts; Ron T Gansevoort; Joris P Slaets
Journal:  PLoS One       Date:  2011-02-10       Impact factor: 3.240

8.  Cognitive screening in patients with intracranial tumors: validation of the BCSE.

Authors:  Juliane Becker; Elisabeth Steinmann; Maria Könemann; Sonja Gabske; Hubertus Maximilian Mehdorn; Michael Synowitz; Gesa Hartwigsen; Simone Goebel
Journal:  J Neurooncol       Date:  2016-02-01       Impact factor: 4.130

9.  The five-point test: reliability, validity and normative data for children and adults.

Authors:  Lara Tucha; Steffen Aschenbrenner; Janneke Koerts; Klaus W Lange
Journal:  PLoS One       Date:  2012-09-24       Impact factor: 3.240

10.  Longitudinal study of performance on the Ruff Figural Fluency Test in persons aged 35 years or older.

Authors:  Marlise E A van Eersel; Hanneke Joosten; Janneke Koerts; Ron T Gansevoort; Joris P J Slaets; Gerbrand J Izaks
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.